Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AVSOLA vs ERELZI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tumor necrosis factor (TNF) alpha inhibitor; AVSOLA (infliximab-axxq) is a chimeric monoclonal antibody that binds with high affinity to soluble and transmembrane forms of TNF-alpha, thereby inhibiting binding of TNF-alpha to its receptors (TNFR1 and TNFR2) and reducing pro-inflammatory cytokine signaling.
Erelzi (etanercept-szzs) is a tumor necrosis factor (TNF) blocker. It is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) TNF receptor linked to the Fc portion of human Ig G1. Erelzi binds specifically to TNF-alpha and blocks its interaction with cell surface TNF receptors, thereby reducing TNF-mediated inflammatory responses.
Crohn's disease (moderate to severe, fistulizing),Pediatric Crohn's disease (moderate to severe),Ulcerative colitis (moderate to severe),Pediatric ulcerative colitis (moderate to severe),Rheumatoid arthritis (in combination with methotrexate),Ankylosing spondylitis,Psoriatic arthritis,Plaque psoriasis (chronic severe)
Rheumatoid arthritis (moderately to severely active),Polyarticular juvenile idiopathic arthritis (moderate to severe),Psoriatic arthritis,Ankylosing spondylitis,Plaque psoriasis (chronic moderate to severe)
5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.
For plaque psoriasis: 100 mg subcutaneous injection once weekly, after initial loading dose of 200 mg at weeks 0, 1, 2, 3, and 4. For psoriatic arthritis: 100 mg subcutaneous injection once weekly.
Terminal elimination half-life is approximately 14–18 days (range 10–39 days) in adults. Prolonged half-life supports dosing every 8 weeks; it is influenced by inflammation and disease severity.
Terminal elimination half-life: 13–16 days (mean 14.6 days) in adults with moderate-to-severe plaque psoriasis; clinical context: supports every-2-week subcutaneous dosing regimen.
Infliximab is a monoclonal antibody; metabolism is via catabolism into peptides and amino acids through general protein degradation pathways (reticuloendothelial system). No involvement of CYP450 enzymes.
Erelzi is a monoclonal antibody-based fusion protein. It is expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes have been identified; it is not metabolized by cytochrome P450 enzymes.
Primarily cleared by the reticuloendothelial system via proteolytic degradation. Minimal renal excretion (less than 1% unchanged) and no significant biliary or fecal elimination.
Renal: negligible (not significantly excreted unchanged); Biliary/Fecal: primary elimination pathway via proteolytic catabolism to amino acids; approximately 95% of dose recovered as small peptides/amino acids in feces.
Predominantly bound to soluble TNF-alpha; no specific plasma protein binding (e.g., albumin) is reported; the complex is cleared, so free drug binding is low.
Approximately 95–98% bound; primarily to endogenous immunoglobulins (Ig G) via Fc Rn binding; minimal binding to albumin or other plasma proteins.
Volume of distribution is approximately 0.04–0.06 L/kg, indicating limited tissue distribution primarily within the vascular space.
Volume of distribution: 3.5–4.0 L (approximately 0.05 L/kg for a 70 kg adult), indicating limited extravascular distribution, predominantly confined to vascular space and interstitial fluid.
Bioavailability is 100% after intravenous infusion; no other routes are clinically relevant.
Subcutaneous: absolute bioavailability approximately 75–80% following injection into thigh, abdomen, or upper arm.
No dose adjustment required for renal impairment.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²); use with caution.
No formal studies; use caution in hepatic impairment.
No formal studies in hepatic impairment. Use with caution in Child-Pugh Class B or C due to potential altered clearance.
5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks; approved for ages 6 years and older.
Safety and efficacy not established in pediatric patients <18 years old; no approved dosing.
No specific dose adjustment; monitor for infections and adverse effects.
No specific dose adjustment recommended based on age alone; monitor for adverse effects due to potential age-related decreases in renal function.
WARNING: SERIOUS INFECTIONS and MALIGNANCY. Increased risk of serious infections (including tuberculosis, bacterial sepsis, invasive fungal infections) leading to hospitalization or death; increased risk of lymphoma and other malignancies, including fatal hepatosplenic T-cell lymphoma in adolescents and young adults with inflammatory bowel disease.
WARNING: SERIOUS INFECTIONS AND MALIGNANCY. Patients treated with TNF blockers, including Erelzi, are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue Erelzi if a patient develops a serious infection. Reported infections include: active tuberculosis (including reactivation of latent TB), invasive fungal infections (e.g., histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis), and bacterial, viral, or other opportunistic infections. Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with TNF blockers.
Risk of serious infections (screen for latent TB and treat before initiation, monitor for active infections),Hypersensitivity reactions (including anaphylaxis, serum sickness),Hepatotoxicity (including hepatic failure, acute liver injury),Reactivation of hepatitis B virus,Hematologic toxicity (pancytopenia, leukopenia),Neurologic events (demyelinating disorders, seizure, optic neuritis),Heart failure exacerbation,Lupus-like syndrome,Immunogenicity (development of anti-drug antibodies leading to infusion reactions and loss of response),Malignancy (especially lymphoma, leukemia, melanoma, and Merkel cell carcinoma)
Serious infections: Do not start Erelzi in patients with active infections. Monitor for signs/symptoms of infection during treatment.,Malignancies: Risk of lymphoma and other malignancies; higher in children and adolescents.,Hepatitis B reactivation: Screen for HBV before starting therapy; discontinue if reactivation occurs.,Demyelinating disorders: Rare cases of CNS demyelinating disorders (e.g., multiple sclerosis, optic neuritis) reported; use caution in patients with pre-existing or recent-onset demyelinating disorders.,Congestive heart failure: Use caution in patients with heart failure; discontinue if new or worsening symptoms occur.,Hematologic events: Pancytopenia, aplastic anemia reported; advise patients to seek medical attention if signs of blood dyscrasias develop.,Hypersensitivity: Serious allergic reactions (including anaphylaxis) have been reported; discontinue if reaction occurs.,Immunizations: Avoid live vaccines during therapy.
History of severe hypersensitivity to infliximab or any murine proteins,Moderate to severe heart failure (NYHA class III/IV),Active serious infections (including sepsis, abscesses, tuberculosis, opportunistic infections),Concurrent use with abatacept or anakinra (increased risk of infection)
Severe infections including sepsis,Known hypersensitivity to etanercept or any component of the product
No known food interactions. AVSOLA is administered intravenously, and its absorption is not affected by oral intake. However, patients should maintain a balanced diet to support immune function.
No known food interactions. Grapefruit and other foods do not affect bimekizumab. However, maintain a balanced diet. If you have a history of liver disease, follow any dietary recommendations provided by your healthcare provider, but there are no specific restrictions.
AVSOLA (infliximab-axxq) is a monoclonal antibody. Ig G crosses the placenta, with increasing transfer during the second and third trimesters. First trimester exposure is associated with low risk of major malformations. Second and third trimester exposure may increase risk of fetal immunosuppression, including neonatal lymphopenia, and vaccination risks. Avascular necrosis and congenital anomalies have been reported post-marketing but causal relationship not established. Avoid live vaccines in infants exposed in utero for 6 months.
Pregnancy Category N. No adequate animal reproduction studies. No well-controlled human studies. At therapeutic doses, immunomodulatory effects may theoretically increase risk of pregnancy loss and congenital anomalies. First trimester exposure: unknown teratogenic risk. Second and third trimester: potential for adverse fetal immune effects.
Infliximab is excreted in breast milk in small amounts; M/P ratio (milk to plasma ratio) is approximately 0.001-0.002. Oral bioavailability in infants is low due to gastrointestinal degradation. Limited data show no adverse effects in breastfed infants. However, consider maternal dosage, infant age, and risk of immunosuppression. Benefit of breastfeeding likely outweighs minimal risk.
No data on presence in breast milk. M/P ratio unknown. Maternal Ig G is known to be excreted in breast milk; as a monoclonal antibody, Erelzi may be present. Caution recommended, especially in preterm infants or those with compromised gastrointestinal barrier.
Pharmacokinetics of infliximab may be altered due to increased plasma volume, renal clearance, and third-spacing during pregnancy. However, no specific dose adjustment guidelines are established. Most studies recommend maintaining standard dosing throughout pregnancy to ensure therapeutic levels. Monitor clinical response and consider therapeutic drug monitoring if needed. Postpartum, no dose adjustment required, but reassess for disease flare.
No established dose adjustments for pregnancy. Pharmacokinetics of monoclonal antibodies may change due to increased plasma volume and altered metabolism. Consider therapeutic drug monitoring if available, but lack of data precludes specific dose changes.
AVSOLA (infliximab-axxq) is a biosimilar to Remicade. Pre-medicate with antihistamines and acetaminophen to reduce infusion reactions. Screen for latent TB (PPD or IGRA) and HBV before initiation. Do not administer live vaccines during therapy. Monitor for signs of infection, including opportunistic infections like histoplasmosis. Discontinue if symptoms of lupus-like syndrome or severe hepatotoxicity occur. Infusion reactions may occur up to 2 hours post-infusion; have emergency equipment available.
ERELZI (bimekizumab) is a humanized monoclonal Ig G1 antibody that selectively inhibits IL-17A and IL-17F. For plaque psoriasis, consider loading dose: 320 mg (two 160 mg injections) subcutaneously at weeks 0, 4, 8, then 320 mg every 8 weeks. Monitor for hypersensitivity reactions and infections. May elevate liver enzymes; check baseline and periodic LFTs. Avoid live vaccines. Can be used with caution in patients with history of inflammatory bowel disease. Injection site reactions are common; rotate sites. Not recommended in pregnancy unless benefit outweighs risk.
AVSOLA is given as an IV infusion over at least 2 hours; you will be monitored during and after infusion.,Report any signs of allergic reaction (hives, difficulty breathing, swelling) immediately.,Seek medical help if you develop fever, chills, persistent cough, or skin changes.,Do not receive live vaccines while on AVSOLA; update vaccinations before starting.,Avoid becoming pregnant during treatment; use effective contraception.,Notify your doctor of any new or worsening symptoms, including chest pain or shortness of breath.
ERELZI is given as an injection just under the skin; you or a caregiver can be trained to inject at home.,Store in refrigerator at 36°F to 46°F (2°C to 8°C); do not freeze. Protect from light. Let it sit at room temperature for 30 minutes before injecting.,Do not use if solution is cloudy, discolored, or contains particles.,Tell your doctor if you have any signs of infection (fever, chills, cough, painful urination) or allergic reaction (rash, itching, difficulty breathing).,Avoid live vaccines during treatment.,You may need blood tests to check your liver function before and during treatment.,Seek medical attention if you develop symptoms of inflammatory bowel disease (new or worsening abdominal pain, diarrhea, blood in stool).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AVSOLA vs ERELZI, answered by our medical review team.
AVSOLA is a TNF-Alpha Inhibitor that works by Tumor necrosis factor (TNF) alpha inhibitor; AVSOLA (infliximab-axxq) is a chimeric monoclonal antibody that binds with high affinity to soluble and transmembrane forms of TNF-alpha, thereby inhibiting binding of TNF-alpha to its receptors (TNFR1 and TNFR2) and reducing pro-inflammatory cytokine signaling.. ERELZI is a TNF-alpha Inhibitor that works by Erelzi (etanercept-szzs) is a tumor necrosis factor (TNF) blocker. It is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) TNF receptor linked to the Fc portion of human Ig G1. Erelzi binds specifically to TNF-alpha and blocks its interaction with cell surface TNF receptors, thereby reducing TNF-mediated inflammatory responses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AVSOLA and ERELZI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AVSOLA is: 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.. The standard adult dose of ERELZI is: For plaque psoriasis: 100 mg subcutaneous injection once weekly, after initial loading dose of 200 mg at weeks 0, 1, 2, 3, and 4. For psoriatic arthritis: 100 mg subcutaneous injection once weekly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AVSOLA and ERELZI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AVSOLA is classified as Category C. AVSOLA (infliximab-axxq) is a monoclonal antibody. IgG crosses the placenta, with increasing transfer during the second and third trimesters. First trimester exposure is associated. ERELZI is classified as Category C. Pregnancy Category N. No adequate animal reproduction studies. No well-controlled human studies. At therapeutic doses, immunomodulatory effects may theoretically increase risk of p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.